At what level will your practice participate in MIPS this year? Here’s what you need to know to start documenting performance data this year.
Predictive modeling data can steer physicians toward making healthcare decisions that have positive outcomes for patients.
Improving care for high-need, high-cost patients is an imperative for patients and the healthcare system. Programs are in development, NEJM perspective reports.
Providers with a limited practice scope should be prepared to participate in collaborative care or reimbursement under MACRA could suffer, Dr. Edward Lin says.
Rheumatologists face unique challenges not fully addressed in CMS' Quality Payment Program, says CSRO's Dr. Michael Schweitz. Dr. Schweitz addresses these challenges in this blog post.
Prem N. Ramkumar, M.D., the author of a recent analysis on readmission rates in TJA, speaks with Rheumatology Network about why readmission rates matter.
Physicians should understand the key features of MACRA and changes that lie ahead, say Duke University healthcare policy experts writing in JAMA
Physicians should understand the key features of MACRA and changes that lie ahead, say Duke University healthcare policy experts writing in JAMA.
Higher price tags and greater cost-sharing in specialty medicine may force patients to forego, delay or reduce treatment, a study shows.
In this op-ed, specialty medicine experts address the value of biosimilars in specialty care. Value, they write, is a "three-legged stool supported by efficacy, toxicity and cost."